Drug Shortage Report for TOBRAMYCIN FOR INJECTION
Report ID | 245141 |
Drug Identification Number | 00533688 |
Brand name | TOBRAMYCIN FOR INJECTION |
Common or Proper name | TOBRAMYCIN FOR INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | TOBRAMYCIN |
Strength(s) | 1.2G |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
Additional packaging sizes | 50 mL |
ATC code | J01GB |
ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | 2024-12-10 |
Actual start date | |
Estimated end date | 2025-01-24 |
Actual end date | 2025-01-17 |
Shortage status | Resolved |
Updated date | 2025-01-22 |
Company comments | Fresenius Kabi Canada regrets to advise that we will be encountering a supply interruption on our Tobramycin for Injection 1.2 g PBP Vial 50 mL effective December 10, 2024, until January 24, 2025. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2025-01-22 | French | Compare |
v4 | 2025-01-22 | English | Compare |
v3 | 2024-12-11 | English | Compare |
v2 | 2024-12-09 | French | Compare |
v1 | 2024-12-09 | English | Compare |
Showing 1 to 5 of 5